Monopar Therapeutics, Inc.

( )
MNPR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.76%167.520.0%$1577.49m
NVAXNovavax, Inc. -2.13%90.3678.2%$619.81m
AMGNAmgen, Inc. -1.04%228.901.4%$514.94m
BIIBBiogen, Inc. -2.12%225.911.8%$488.90m
GILDGilead Sciences, Inc. -1.82%67.811.0%$457.29m
BNTXBioNTech SE -3.17%156.530.0%$424.65m
REGNRegeneron Pharmaceuticals, Inc. -0.60%614.382.7%$390.30m
ILMNIllumina, Inc. -1.02%380.443.3%$382.15m
VRTXVertex Pharmaceuticals, Inc. -0.97%228.611.9%$331.12m
SNSSSunesis Pharmaceuticals, Inc. -4.17%2.760.7%$192.93m
EXASEXACT Sciences Corp. -0.13%76.0317.9%$160.43m
ARNAArena Pharmaceuticals, Inc. -0.55%91.0113.7%$137.96m
ALNYAlnylam Pharmaceuticals, Inc. -0.22%138.318.2%$131.22m
INCYIncyte Corp. -0.03%74.762.4%$129.57m
BMRNBioMarin Pharmaceutical, Inc. -1.80%84.454.2%$102.33m

Company Profile

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The firm engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.